Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:40 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 7,083 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Terminated No phase listed Observational

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

NCT01532232
View directory record Official record
Conditions
Breast Cancer, Tobacco Dependence
Interventions
placebo, varenicline
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Nov 3, 2026, 8:40 PM EST
Completed No phase listed Observational

Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies

NCT00341263
View directory record Official record
Conditions
Normal Pregnancy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Nov 3, 2026, 8:40 PM EST
Completed No phase listed Observational

Quantitative Dynamic Contrast Enhanced Breast MRI

NCT00582764
View directory record Official record
Conditions
Breast Cancer
Interventions
perform dynamic contrast enhanced (DCE) MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Nov 3, 2026, 8:40 PM EST
Recruiting Phase 2 Interventional

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

NCT07158021
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Goserelin, Leuprolide, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 8:40 PM EST
Completed Early Phase 1 Interventional

Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes

NCT00360152
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Fine needle aspiration biopsy (FNAB), Sentinel Lymph Node Biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Nov 3, 2026, 8:40 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 8:40 PM EST
Withdrawn Phase 2 Interventional

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

NCT00003536
View directory record Official record
Conditions
Stage IV Breast Cancer, Recurrent Breast Cancer
Interventions
antineoplaston A10, methotrexate, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, chemotherapy, complementary and alternative therapy, differentiation therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Nov 3, 2026, 8:40 PM EST
Completed Not applicable Interventional Results available

LLLT Combined With CDT in Breast Cancer-Related Lymphedema

NCT01351376
View directory record Official record
Conditions
Breast Cancer, Lymphedema
Interventions
Low Level Laser Therapy, Low Level Laser
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Nov 3, 2026, 8:40 PM EST
Completed No phase listed Observational

Understanding Value in Metastatic Breast Cancer

NCT03257917
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Understanding value in Metastatic Breast Cancer
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 1 Interventional

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

NCT00268918
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
Interventions
Docetaxel, PTK787
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 3 Interventional

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

NCT00002920
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
medroxyprogesterone, tamoxifen citrate, adjuvant therapy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
122
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Nov 3, 2026, 8:40 PM EST
Completed No phase listed Observational Accepts healthy volunteers

4R for Guideline Indicated BRCA Testing of Breast Center Patients

NCT01320540
View directory record Official record
Conditions
Newly Diagnosed Carcinoma of Breast, Genetic Predisposition to Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Nov 3, 2026, 8:40 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

NCT04081779
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Lymphoma, Prostate Carcinoma
Interventions
Survivorship Care Plan, Educational Intervention, Questionnaire Administration, Supportive Care
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 8:40 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers

NCT00909662
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults
Interventions
assessment of therapy complications, cognitive assessment, fatigue assessment and management
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 2 Interventional Results available

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Nov 3, 2026, 8:40 PM EST
Completed Not applicable Interventional

OA for Breast Cancer NAC Response

NCT05337280
View directory record Official record
Conditions
Breast Cancer
Interventions
Imagio OA/US
Device
Lead sponsor
Seno Medical Instruments Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

NCT00087178
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, adriamycin, epirubicin, fluorouracil
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
2,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
586
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 396 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 1 Interventional

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00637897
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, ixabepilone, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, paricalcitol
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 8:40 PM EST
Terminated No phase listed Observational

Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage

NCT00156260
View directory record Official record
Conditions
Breast Cancer
Interventions
Ductal lavage
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Nov 3, 2026, 8:40 PM EST
Recruiting Phase 2 Interventional

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

NCT05464082
View directory record Official record
Conditions
Breast Cancer Recurrent
Interventions
Functional Precision Oncology
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:40 PM EST
Withdrawn Not applicable Interventional

TNBC Gut Microbiota During Neoadjuvant Treatment

NCT06610097
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
Interventions
Nutritional Counseling
Other
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy

NCT01740323
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Curcumin
Drug
Lead sponsor
Andrew H Miller
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Nov 3, 2026, 8:40 PM EST
Recruiting Not applicable Interventional

Strength After Breast Cancer

NCT06052488
View directory record Official record
Conditions
Breast Cancer
Interventions
Strength After Breast Cancer
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 3, 2026, 8:40 PM EST
Completed Phase 1 Interventional

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

NCT01588678
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-3078a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Nov 3, 2026, 8:40 PM EST